Sun Pharmaceutical Industries announced on Monday its plan to acquire Checkpoint Therapeutics, Inc., a company specializing in immunotherapy and targeted oncology, for up to $355 million.
Under the agreement, Sun Pharma will pay an upfront price of $4.10 per share of common stock, amounting to a total upfront consideration of up to $355 million, the company stated.
Additionally, Checkpoint stockholders will receive a contingent value right of up to $0.70 per share upon achieving a specified milestone.